Trial reportDiabetologia2011
Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.
Trial report in Diabetologia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 54 citations in OpenAlex.
- Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study.Drug design, development and therapy · 2019Trial
- The Unique Ethnicity-Specific Aspects of Burden, Pathogenesis and Management of Prediabetes: Insights from Africa.Current diabetes reports · 2025Review
- Liver Fat Scores for Noninvasive Diagnosis and Monitoring of Nonalcoholic Fatty Liver Disease in Epidemiological and Clinical Studies.Journal of clinical and translational hepatology · 2023Review
- Beta-cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced?Journal of diabetes · 2023Review
- Should Prediabetes be Treated Pharmacologically?Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Prediabetes and Fracture Risk Among Midlife Women in the Study of Women's Health Across the Nation.JAMA network open · 2023Article
- PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling.The Journal of pharmacy and pharmacology · 2018Article
- Dietary Fat Intake Modulates Effects of a Frequent ACE Gene Variant on Glucose Tolerance with association to Type 2 Diabetes.Scientific reports · 2017Article
- Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.The Journal of clinical endocrinology and metabolism · 2016Article
- Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes.European heart journal · 2016Article
- The metabolic vascular syndrome - guide to an individualized treatment.Reviews in endocrine & metabolic disorders · 2016Review
- Pharmacological treatment and therapeutic perspectives of metabolic syndrome.Reviews in endocrine & metabolic disorders · 2014Review
- Antihypertensive drugs and glucose metabolism.World journal of cardiology · 2014Review
- Prediabetes and lifestyle modification: time to prevent a preventable disease.The Permanente journal · 2014Article
- Prediabetes: a high-risk state for diabetes development.Lancet (London, England) · 2012Review
- Article
- Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications.The review of diabetic studies : RDSReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisThe Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial reported that 3 years of therapy with rosiglitazone reduced the primary outcome of diabetes or death by 60%. Here we investigated whether an effect on diabetes prevention persists more than 1.5 years after therapy has been discontinued.
methodsThe DREAM On passive follow-up study was conducted at 49 of the 191 DREAM sites. Consenting participants were invited to have a repeat OGTT 1-2 years after active therapy ended. A diagnosis of diabetes at that time was based on either a fasting or 2 h plasma glucose level of ≥7.0 mmol/l or ≥11.1 mmol/l, respectively, or a confirmed diagnosis by a non-study physician. Regression to normoglycaemia was defined as a fasting and 2 h plasma glucose level of <6.1 mmol/l and <7.8 mmol/l, respectively.
resultsAfter a median of 1.6 years after the end of the trial and 4.3 years after randomisation, rosiglitazone participants had a 39% lower incidence of the primary outcome (hazard ratio [HR] 0.61, 95% CI 0.53-0.70; p < 0.0001) and 17% more regression to normoglycaemia (95% CI 1.01-1.34; p = 0.034). When the analysis was restricted to the passive follow-up period, a similar incidence of both the primary outcome and regression was observed in people from both treatment groups (HR 1.00, 95% CI 0.81-1.24 and HR 1.14, 95% CI 0.97-1.32, respectively). Similar effects were noted when new diabetes was analysed separately from death. Ramipril did not have any significant long-term effect. CONCLUSIONS/
interpretationTime-limited exposure to rosiglitazone reduces the longer term incidence of diabetes by delaying but not reversing the underlying disease process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.